semaglutide anxiety depression GLP-1 Drug Improved Motivation in Major Depressive Disorder Study links semaglutide and tirzepatide

This story is part of Project Remission, a digital series from the American College of Lifestyle Medicine produced in partnership with Content With Purpose

Semaglutide's higher efficacy can be attributed to its longer half-life, more potent effects on appetite suppression, and greater impact on insulin regulation

These patterns show a transition from calorie reduction toward sustaining daily health and physical resilience

Importantly, Zepbound carries a Boxed Warning for risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

Aronne has been part of multiple studies on GLP-1s, including the SURMOUNT-1 trial designed to see how well combining lifestyle changes and tirzepatide works in people on the verge of diabetes